SCOPUS 정보 검색 플랫폼

Archives of Internal Medicine

Volumn 171, Issue 6, 2011, Pages 591-593

The FDA drug safety surveillance program: Adverse event reporting trends

(4) Weiss Smith, Sheila a Deshpande, Gaurav a Chung, Stephanie b Gogolak, Victor b

a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY (United States)

b DrugLogic (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; ETANERCEPT; ETHINYLESTRADIOL PLUS NORELGESTROMIN; EXENDIN 4; INFLIXIMAB; LEVONORGESTREL; PARATHYROID HORMONE[1-34]; QUETIAPINE; ROFECOXIB;

ARTICLE; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HUMAN; PHYSICIAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955155332 PISSN: 00039926 EISSN: 15383679 Source Type: Journal
DOI: 10.1001/archinternmed.2011.89 Document Type: Article

Times cited : (46)

References (8)

1
- 0035210598
- The role of databases in drug postmarketing surveillance
- Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407-410.
- (2001) Pharmacoepidemiol Drug Saf , vol.10 , Issue.5 , pp. 407-410
- Rodriguez, E.M.¹ Staffa, J.A.² Graham, D.J.³

2
- 22144474788
- Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions
- Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363-1369.
- (2005) Arch Intern Med , vol.165 , Issue.12 , pp. 1363-1369
- Wysowski, D.K.¹ Swartz, L.²

3
- 34548602369
- Serious adverse drug events reported to the Food and Drug Administration, 1998-2005
- Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167(16):1752-1759.
- (2007) Arch Intern Med , vol.167 , Issue.16 , pp. 1752-1759
- Moore, T.J.¹ Cohen, M.R.² Furberg, C.D.³

4
- 79955150659
- US Food and Drug Administration, Revised April 1, CFR §314.80
- US Food and Drug Administration. Postmarketing reporting of adverse drug experiences. Revised April 1, 2009. 21 CFR §314.80.
- (2009) Postmarketing reporting of adverse drug experiences , pp. 21

5
- 79955146952
- Web site, Accessed November 30, 2007
- MedDRA MSSO Web site. http://www.meddramsso.com/index.asp. Accessed November 30, 2007.

6
- 79953678328
- US Food and Drug Administration, Accessed August 26, 2010
- US Food and Drug Administration. Reports received and reports entered into AERS by year. http://www.fda.gov/Drugs/GuidanceComplianceRegulatory-Information/Surveillance/AdverseDrugEffects/ucm070434.htm. Accessed August 26, 2010.
- Reports received and reports entered into AERS by year

7
- 0037024691
- National ambulatory medical care survey: 2000 summary
- Cherry DK, Woodwell DA. National ambulatory medical care survey: 2000 summary. Adv Data. 2002;(328):1-32.
- (2002) Adv Data , Issue.328 , pp. 1-32
- Cherry, D.K.¹ Woodwell, D.A.²

8
- 0037024691
- National ambulatory medical care survey: 2005 summary
- Cherry DK, Woodwell DA, Rechtsteiner EA. National ambulatory medical care survey: 2005 summary. Adv Data. 2007;(387):1-39.
- (2007) Adv Data , Issue.387 , pp. 1-39
- Cherry, D.K.¹ Woodwell, D.A.² Rechtsteiner, E.A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.